IONS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IO

Mkt Cap

$7.14B

Volume

1.34M

Next Earnings

November 4th

Loading chart

IO

IONSIonis Pharmaceuticals, Inc. Common Stock

IONS

Pay with—

Available Balance0.00

IO

Mkt Cap

$7.14B

Volume

1.34M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

NVS Wins FDA Nod for Label Expansion of Immunology Drug RhapsidoNovartis received FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism (SD), making it the only prescription treatment approved for both CSU and SD, the two most common forms of chronic hives. The approval was supported by phase III RemIND trial data showing 29.3% complete hive resolution at week 12 versus 14% for placebo. The company is also evaluating remibrutinib in multiple sclerosis, hidradenitis suppurativa, and food allergy. However, Novartis faces pipeline setbacks with failed trials for pelacarsen and del-desiran, and generic competition pressuring blockbuster drugs.Zacks Investment Research · Oct 8, 2026

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNovartis entered into a licensing agreement with Abogen Biosciences to acquire exclusive worldwide rights to ABO2203, an mRNA-encoded T-cell engager for autoimmune diseases. The deal includes a $575 million upfront payment and up to $7.2 billion in milestone payments. This move aims to strengthen Novartis' immunology pipeline following recent clinical setbacks in pelacarsen and del-desiran programs.Zacks Investment Research · Oct 5, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.The Motley Fool · Oct 1, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.Despite being down 35% year-to-date, Alnylam Pharmaceuticals has rebounded 25% since late July and maintains strong analyst support with 18 of 21 analysts rating it as a buy or strong buy. The stock's attractive valuation (19.7x forward earnings, 0.32 PEG ratio) and favorable market dynamics—including reduced competition from a failed rival drug and extended patent protection for Pfizer's competing therapy—support the bullish outlook. However, investors should monitor demand normalization for Amvuttra and potential developments from the failed Wainua trial.The Motley Fool · Sep 28, 2026

Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsIonis Pharmaceuticals announced positive phase III results for two partnered programs: ulefnersen (FUSION study) for FUS-ALS met its primary endpoint with Otsuka planning regulatory discussions, and sefaxersen (IMAgINATION study) for IgAN showed statistically significant proteinuria reductions with Roche continuing the trial. These wins come after recent clinical setbacks in cardiovascular programs but follow FDA approval of Zanvastro for Alexander disease.Zacks Investment Research · Sep 23, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish OutlookIonis Pharmaceuticals stock has plummeted over 40% this year due to late-stage clinical trial failures and ongoing losses, yet Wall Street analysts maintain a bullish outlook with an average price target of $83.82. Despite setbacks with pelacarsen and eplontersen programs, the company's strong ASO technology platform, solid $2.1 billion cash position, and recent FDA approval of Zanvastro for Alexander disease provide potential for long-term investors willing to wait several years for profitability.The Motley Fool · Sep 20, 2026

Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AstraZeneca's stock has declined following several late-stage pipeline failures including Wainua in ATTR-CM, Ultomiris in HSCT-TMA, volrustomig in NSCLC, and Etcamah in breast cancer. However, the company maintains a broad pipeline with over 20 expected high-value readouts in the next 18 months, particularly in oncology. The stock trades at a reasonable valuation of 16.29x forward earnings, below industry average, though 2026-2027 earnings estimates have been revised downward.Zacks Investment Research · Sep 18, 2026

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?Amneal Pharmaceuticals shares surged 8.6% following completion of its Kashiv BioSciences acquisition, creating an integrated biosimilars platform. However, consensus EPS estimates were revised 23.1% lower over the past month, which could limit future gains. Ionis Pharmaceuticals declined 5.1% with unchanged negative EPS expectations.Zacks Investment Research · Sep 17, 2026

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsThe global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.GlobeNewswire Inc. · Sep 15, 2026

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?Theravance Biopharma reported Q2 2026 earnings matching estimates with revenues of $20.7 million, marginally beating consensus. The stock has gained 0.8% since the earnings report. The company achieved profitability with adjusted EPS of 19 cents versus a loss a year ago, driven by Yupelri collaboration revenues and significant cost-cutting measures. However, analysts remain quiet with no estimate revisions, and the stock carries a Zacks Rank #3 (Hold) rating with poor growth and momentum scores.Zacks Investment Research · Sep 9, 2026

to start trading

IO

IONSIonis Pharmaceuticals, Inc. Common Stock

IONS

Pay with—

Available Balance0.00

Your PositionYou don't own any IONS yet.

Related Tickers

Earnings